Skip to content.Skip to side navigation. Quick Navigation: Skip to content.Skip to side navigation.
GPO Access Home Page.
Jump to selected topic.
Navigation Bar
About.Help. A-Z Resource List. Locate a Federal Depository Library. Buy Publications. Legislative. Executive. Judicial.
National Archives and Records Administration logo.
Database Features.
Browse
Simple Search
Advanced Search
* Boolean
  * Proximity
Search History
Search Tips
Corrections

Latest Updates

User Info
FAQs
Agency List
Incorporation by Reference
e-CFR Main Page
Related Resources
Code of Federal Regulations
Federal Register
List of CFR
Sections Affected
Regulations.gov
Unified Agenda
All NARA Publications
About Government.
Ben's Guide Logo.
Get Adobe Reader

blue pill
e-CFR Data is current as of November 19, 2009


Title 21: Food and Drugs
PART 312—INVESTIGATIONAL NEW DRUG APPLICATION
Subpart A—General Provisions

Browse Previous

§ 312.10   Waivers.

(a) A sponsor may request FDA to waive applicable requirement under this part. A waiver request may be submitted either in an IND or in an information amendment to an IND. In an emergency, a request may be made by telephone or other rapid communication means. A waiver request is required to contain at least one of the following:

(1) An explanation why the sponsor's compliance with the requirement is unnecessary or cannot be achieved;

(2) A description of an alternative submission or course of action that satisfies the purpose of the requirement; or

(3) Other information justifying a waiver.

(b) FDA may grant a waiver if it finds that the sponsor's noncompliance would not pose a significant and unreasonable risk to human subjects of the investigation and that one of the following is met:

(1) The sponsor's compliance with the requirement is unnecessary for the agency to evaluate the application, or compliance cannot be achieved;

(2) The sponsor's proposed alternative satisfies the requirement; or

(3) The applicant's submission otherwise justifies a waiver.

[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 67 FR 9585, Mar. 4, 2002]

Browse Previous